Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage development.
Lu Y, Liang S, Hong Y, Tajima N, Patel K, Li H, Wada DR, Greenberg J, Petrich A, Zebger-Gong H, Shuster D, Vaddady P. Lu Y, et al. Among authors: wada dr. CPT Pharmacometrics Syst Pharmacol. 2024 Jan;13(1):23-28. doi: 10.1002/psp4.13058. Epub 2023 Nov 1. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 37915242 Free PMC article. Clinical Trial.
Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin®), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors.
Quartino AL, Li H, Kirschbrown WP, Mangat R, Wada DR, Garg A, Jin JY, Lum B. Quartino AL, et al. Among authors: wada dr. Cancer Chemother Pharmacol. 2019 Feb;83(2):329-340. doi: 10.1007/s00280-018-3728-z. Epub 2018 Nov 22. Cancer Chemother Pharmacol. 2019. PMID: 30467591 Free PMC article.
Assessment of cabozantinib treatment on QT interval in a phase 3 study in medullary thyroid cancer: evaluation of indirect QT effects mediated through treatment-induced changes in serum electrolytes.
Miles DR, Lacy SA, Wada DR, Milwee S, Yaron Y, Nguyen LT. Miles DR, et al. Among authors: wada dr. Cancer Chemother Pharmacol. 2017 Aug;80(2):295-306. doi: 10.1007/s00280-017-3349-y. Epub 2017 Jun 20. Cancer Chemother Pharmacol. 2017. PMID: 28634649 Clinical Trial.
Pharmacokinetic and exposure-response analyses of pertuzumab in combination with trastuzumab and docetaxel during neoadjuvant treatment of HER2+ early breast cancer.
Quartino AL, Li H, Jin JY, Wada DR, Benyunes MC, McNally V, Viganò L, Nijem I, Lum BL, Garg A. Quartino AL, et al. Among authors: wada dr. Cancer Chemother Pharmacol. 2017 Feb;79(2):353-361. doi: 10.1007/s00280-016-3218-0. Epub 2017 Jan 10. Cancer Chemother Pharmacol. 2017. PMID: 28074265 Free PMC article.
Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
Garg A, Quartino A, Li J, Jin J, Wada DR, Li H, Cortés J, McNally V, Ross G, Visich J, Lum B. Garg A, et al. Among authors: wada dr. Cancer Chemother Pharmacol. 2014 Oct;74(4):819-29. doi: 10.1007/s00280-014-2560-3. Epub 2014 Aug 14. Cancer Chemother Pharmacol. 2014. PMID: 25119184
29 results